eISSN: 1644-4124
ISSN: 1426-3912
Central European Journal of Immunology
Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
3/2018
vol. 43
 
Share:
Share:
abstract:
Clinical immunology

Diversity of dendritic cells generated from umbilical cord or adult peripheral blood precursors

Magdalena Szaryńska
,
Krzysztof Preis
,
Piotr Zabul
,
Zbigniew Kmieć

(Centr Eur J Immunol 2018; 43 (3): 306-313)
Online publish date: 2018/10/30
View full text Get citation
 
PlumX metrics:
Following the discovery of methods to generate large numbers of specific dendritic cells (DCs) ex vivo, the possibility of exploiting these cells in immunotherapeutic strategies will become a reality. It seems to be rationally to analyse the influence of the precursor source for further features and applications.

For the needs of the given project DCs were derived from precursors derived from adult peripheral blood (APB) and umbilical cord blood (UCB). During some expansions of UCB CD34+ cells were separated giving non-adherent DCs (NA-DCs) or adherent DCs (A-DCs), whereas DCs derived from UCB precursors without separation gave rise to All-DCs. DC subpopulations were stimulated by lipopolysaccharides (LPS) or interferon- (IFN-), and afterwards the morphology, phenotype, and stimulatory properties were analysed.

Our findings demonstrated that DCs generated from APB and UCB precursors were not equivalent and exhibited opposite features when expanded in comparable conditions. Additionally, all three subpopulations of UCB-derived DCs presented functional dissimilarities. Based on our results we concluded that the precursor source and the composition of media must be considered as crucial to the success of potential therapeutic application.
keywords:

dendritic cells, haematopoietic stem cells, monocytes

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.